New York, NY -- (SBWire) -- 05/18/2020 --Therapeutic vaccines are biological combinations which develop immunity against a diseased tissue or cell. Therapeutic vaccines are administered to the patient in order to induce a defence mechanism against particular disease. These are developed to treat various cancer diseases, HIV, and Alzheimer's disease etc. Prophylactic vaccines differ from therapeutic vaccines are used for the prevention and control of diseases, while the prophylactic vaccines are only used for prevention of diseases. Therapeutic vaccines are specially manufactured for the HIV positive individuals with the healthy immune system, to increase the ability to fight against microorganisms. Therapeutic vaccines are currently developed for chronic viral infections, such as human immunodeficiency virus (HIV), human papillomavirus (HPV), herpes simplex virus (HSV), cancer, hepatitis B virus, and hepatitis C virus etc. as an alternative to antiviral treatment.
Major Key Players of the Therapeutic Vaccines Market are:
Merck & Co., Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Sanofi-Pasteur (France), Dendreon (U.S.). Agenus Inc. (U.S.), Valeant (Canada), Bavarian Nordic (Denmark), Pfizer, Inc. (U.S.) and Inovio Pharmaceuticals, Inc. (U.S.), to name a few.
Get sample copy of "Therapeutic Vaccines Market" at: https://www.marketgrowthinsight.com/sample/56304?source=shubh
The global therapeutic vaccines market is expected to grow at a significant CAGR due to increase in the prevalence of chronic diseases such as cancer, and HIV etc. According to World Health Organisation, an escalation of the diseases such as cancer (approximately 8.8 Mn people died in 2015) and HIV expected to drive the growth of global therapeutic vaccines market over the forecasting period. The advanced and active R&D activities for therapeutic vaccines by pharmaceutical companies for various types of cancers are in pipeline which is expected to create potential opportunity in the global therapeutic vaccines market in future. Apart from this, rising number of mergers and acquisitions, and an increase in funding from government for development of therapeutic vaccines might fuel the growth of global therapeutic vaccines market over the forecasting period. However, inefficient research and development and non-existent reimbursement policies for vaccines are the primary factors which are expected to hinder the growth of global therapeutic vaccines market. Similarly, stringent regulatory implications, higher cost of vaccines, lesser accessibility to the vaccines, availability of alternative treatments for the diseases, and some adverse effects associated with the vaccines might hamper the growth of global therapeutic vaccines market over the forecast period.
Based on product type, global therapeutic vaccines market has been segmented into the following:
Conjugate vaccines
Live attenuated vaccines
Inactivated and subunit vaccines
Toxoid vaccines
Recombinant vaccines
Based on application, global therapeutic vaccines market has been segmented into the following:
Infectious Diseases
Oncology
Addiction
Autoimmune diseases
Neurological diseases
Others
Based on technology, global therapeutic vaccines market has been segmented into the following:
Autologous vaccines
Allogeneic vaccines
The global therapeutic vaccines market is in the nascent stage where many players are actively involved in the development of therapeutic vaccines. Few companies have adopted some key business strategies, such as product innovation, and new product launching to ensure their dominance in the global therapeutic vaccines market. The global therapeutic vaccines market is positively affected by the significant rise in prevalence of chronic diseases such as cancer, and HIV etc. Few companies have taken an active lead in research and development of therapeutic vaccines. For instance, in April 2010, Dendreon Corporation, launched FDA approved immunotherapy drug Provenge, for the treatment of prostate cancer. According to U.S. Department of Health and Human Services, there are some vaccines in the clinical trial stage, such as Lucanix (Belagenpumatucel-L), gp100 melanoma vaccine, for Non-small cell lung cancer. Similarly, Merck & Co., Inc. and GSK Plc. are expected to launch vaccines such as GSK1572932A, and GV1001 having entered phase 3 trials.
Research objectives:-
– To study and analyze the global Therapeutic Vaccines consumption (value & volume) by key regions/countries, product type and application, history data.
– To understand the structure of the Therapeutic Vaccines market by identifying its various sub-segments.
– Focuses on the key global Therapeutic Vaccines manufacturers, to define, describe and analyze the sales volume, value, market share, market competitive landscape, SWOT analysis, and development plans in the next few years.
– To analyze the Therapeutic Vaccines with respect to individual growth trends, future prospects, and their contribution to the total market.
– To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Go For Interesting Discount Here: https://www.marketgrowthinsight.com/discount/56304?source=shubh
Table of Content
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.5 Market by Application
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Therapeutic Vaccines Market Size
2.2 Therapeutic Vaccines Growth Trends by Regions
2.3 Industry Trends
3 Market Share by Key Players
3.1 Therapeutic Vaccines Market Size by Manufacturers
3.2 Therapeutic Vaccines Key Players Head office and Area Served
3.3 Key Players Therapeutic Vaccines Product/Solution/Service
3.4 Date of Enter into Therapeutic Vaccines Market
3.5 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
4.1 Global Therapeutic Vaccines Sales by Product
4.2 Global Therapeutic Vaccines Revenue by Product
4.3 Therapeutic Vaccines Price by Product
5 Breakdown Data by End User
5.1 Overview
5.2 Global Therapeutic Vaccines Breakdown Data by End User
Have any query? Inquiry about report at: https://www.marketgrowthinsight.com/inquiry/56304?source=shubh
In the end, Therapeutic Vaccines industry report specifics the major regions, market scenarios with the product price, volume, supply, revenue, production, and market growth rate, demand, forecast and so on. This report also presents SWOT analysis, investment feasibility analysis, and investment return analysis.
About Market Growth Insight
Market Growth Insight 100% Subsidiary of Exltech Solutions India, is a one stop solution for market research reports in various business categories. We are serving 100+ clients with 30000+ diverse industry reports and our reports are developed to simplify strategic decision making, on the basis of comprehensive and in-depth significant information, established through wide ranging analysis and latest industry trends.
Contact Us-
Email: sales@marketgrowthinsight.com
Phone: + 91 8956767535
Website: https://www.marketgrowthinsight.com
Therapeutic Vaccines Market to Witness Growth Acceleration During 2019-2025 - Merck & Co, GlaxoSmithKline, Novartis AG
Therapeutic vaccines market estimated to be valued US$ XX Mn in 2018 and poised to grow at CAGR of XX% over 2019-2025. Market for therapeutic vaccines is projected to reach US$ XX Mn by 2025.